ArticleArthritis research & therapy2025
Does extracorporeal shockwave therapy treat leg length discrepancy? an experimental animal study.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ultrasound-Guided Versus Landmark-Based Extracorporeal Shock Wave Therapy for Calcific Shoulder Tendinopathy: An Interventional Clinical Trial.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundExtracorporeal shockwave therapy (ESWT) is widely used to treat musculoskeletal diseases, but its impact on adolescents with unhealed epiphyseal plates is concerning. It remains unclear whether ESWT applied to growth plates promotes or inhibits bone growth. Low energy ESWT does not cause damage of articular cartilage and promotes the growth of articular cartilage. Therefore, the application of ESWT to treat the leg length discrepancy is a possibleoption.
methodsHere, the 96 adolescent rats were used to demonstrate that different levels of ESWT developed different effects on the epiphyseal plate and bone growth. The effects and safety of ESWT on the epiphyseal plate were measured at different energy levels of 0.1, 0.25, and 0.5 mJ/mm² with 800 impulses, 4 Hz at the 7, 13, and 25 weeks.
resultsAdditionally, the treatments promoted the growth and length of the tibia bone as the ESWT application by compared with Sham group. Notably, ESWT stimulated the expression of IL-1β at the 7 week, which then decreased by the 25 week. However, no apoptosis signals and cell death were detected, and there was no tissue damage to the epiphyseal plate. The expression of SOX9, BMP2, and BMP4 was observed in the epiphyseal plate following ESWT, suggesting a role in promoting bone growth.
conclusionOur results suggest that ESWT is a safe therapeutic modality for stimulating bone growth at the epiphyseal plate in adolescents, leading to increased bone length. This approach holds potential for future treatment of patients with leg length discrepancies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.